Raymond James Financial’s Axsome Therapeutics AXSM Stock Holding History

Raymond James Financial’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.3M	Sell	147,766 -2,332	-2%	-$403K	0.01%	1333
2025 Q4	$24.8M	Sell	150,098 -8,591	-5%	-$1.2M	0.01%	1290
2025 Q3	$19.3M	Sell	158,689 -2,723	-2%	-$307K	0.01%	1437
2025 Q2	$16.8M	Buy	161,412 +6,337	+4%	+$671K	0.01%	1494
2025 Q1	$18.1M	Sell	155,075 -19,511	-11%	-$2.22M	0.01%	1384
2024 Q4	$14.8M	Buy	+174,586	New	+$16.1M	0.01%	1532

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial's AXSM Position: Q1 2026 in Review

Raymond James Financial reduced its Axsome Therapeutics (AXSM) stake by 1.6% in Q1 2026, selling an estimated $403K and leaving 147,766 shares worth $24.3M. The position accounts for 0.01% of the portfolio, ranked #1333.

Raymond James Financial first reported a position in AXSM in Q4 2024 and has held it in 6 quarters since. The position peaked at $24.8M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Raymond James Financial held 147,766 shares of Axsome Therapeutics worth $24.3M as of Q1 2026.
Raymond James Financial sold 2,332 Axsome Therapeutics shares in Q1 2026, an estimated $403K.
Axsome Therapeutics made up 0.01% of Raymond James Financial's portfolio in Q1 2026, its #1333 holding.
Raymond James Financial first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Axsome Therapeutics position peaked at $24.8M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.